ArticlePediatric research2026
Choline supplementation in classic homocystinuria: impact on homocysteine and hepatic steatosis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClassic homocystinuria is a sulfur metabolism disorder caused by cystathionine beta synthase (CBS) deficiency. The primary aim of treatment is to maintain plasma homocysteine (Hcy) concentration within the target range. This study investigated choline status and the effect of choline supplementation in CBS-deficient homocystinuria patients with elevated Hcy levels despite standard therapy.
methodsFifteen CBS-deficient homocystinuria patients and 20 controls with normal Hcy levels were enrolled. The study group received 1000 mg/day of choline bitartrate for 8 weeks. The control group was not given any supplements. Anthropometric measurements, biochemical tests, liver magnetic resonance proton density fat fraction imaging, and food consumption records of the participants in the study group were evaluated at baseline and at the end of the study.
resultsAll participants demonstrated inadequate dietary choline intake. Choline supplementation significantly increased plasma free and total choline levels (p < 0.01) and reduced average plasma Hcy levels from 123.1 ± 52.2 to 61.1 ± 42.9 µmol/L (p < 0.01). In three of the four patients with hepatic steatosis at the beginning of the study, the condition regressed with choline supplementation.
conclusionIn conclusion, choline supplementation should be considered in CBS-deficient homocystinuria patients with low plasma choline and high Hcy levels despite standard therapy. IMPACT: Choline supplementation further decreases plasma homocysteine levels in patients with classic homocystinuria who still have elevated plasma homocysteine levels on standard therapy. Choline supplementation led to a remarkable surge in plasma free and total choline levels, which marked a significant breakthrough for classic homocystinuria patients. Remarkably, choline supplementation reversed hepatic steatosis in three out of four patients, highlighting its powerful therapeutic potential.
Indexed as
Identifiers
40987823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.